Allscripts Healthcare Solutions Inc

Find Ratings Reports
MDRX : NASDAQ : Technology
$14.12 | %
Today's Range: 13.87 - 14.15
Avg. Daily Volume: 2,366,600
07/29/16 - 4:00 PM ET

Financial Analysis


ALLSCRIPTS HEALTHCARE SOLTNS's gross profit margin for the first quarter of its fiscal year 2016 has increased when compared to the same period a year ago. Sales and net income have grown, and although the growth in revenues has outpaced the average competitor within the industry, the net income growth has not. ALLSCRIPTS HEALTHCARE SOLTNS has weak liquidity. Currently, the Quick Ratio is 0.81 which shows a lack of ability to cover short-term cash needs. The company's liquidity has increased from the same period last year, indicating improving cash flow.

During the same period, stockholders' equity ("net worth") has increased by 7.81% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is in a position in which financial difficulties could develop in the future.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.



Income Statement Q1 FY16 Q1 FY15
Net Sales ($mil)345.56334.55
EBITDA ($mil)54.742.09
EBIT ($mil)20.250.43
Net Income ($mil)2.05-10.08


Balance Sheet Q1 FY16 Q1 FY15
Cash & Equiv. ($mil)100.1288.48
Total Assets ($mil)2624.322504.75
Total Debt ($mil)599.82572.69
Equity ($mil)1378.01278.09


Profitability Q1 FY16 Q1 FY15
Gross Profit Margin52.7249.24
EBITDA Margin15.8212.58
Operating Margin5.860.13
Sales Turnover0.530.55
Return on Assets0.37-2.22
Return on Equity0.71-4.36
Debt Q1 FY16 Q1 FY15
Current Ratio0.991.04
Debt/Capital0.30.31
Interest Expense6.977.26
Interest Coverage2.910.06


Share Data Q1 FY16 Q1 FY15
Shares outstanding (mil)186.97180.81
Div / share0.00.0
EPS0.01-0.06
Book value / share7.377.07
Institutional Own % n/a n/a
Avg Daily Volume2340884.02498418.0

Valuation


HOLD. ALLSCRIPTS HEALTHCARE SOLTNS's P/E ratio indicates a significant premium compared to an average of 112.16 for the Health Care Technology industry and a significant premium compared to the S&P 500 average of 25.05. To use another comparison, its price-to-book ratio of 1.87 indicates a discount versus the S&P 500 average of 2.81 and a significant discount versus the industry average of 5.75. The price-to-sales ratio is similar to the S&P 500 average, but it is significantly below the industry average, indicating a discount.


Price/Earnings
1 2 3 4 5
premium   discount
  Price/Cash Flow
1 2 3 4 5
premium   discount
MDRX 229.67 Peers 112.16   MDRX 11.48 Peers 23.36

Premium. A higher P/E ratio than its peers can signify a more expensive stock or higher growth expectations.

MDRX is trading at a significant premium to its peers.

 

Discount. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.

MDRX is trading at a significant discount to its peers.

 
Price/Projected
Earnings
1 2 3 4 5
premium   discount
  Price to
Earnings/Growth
1 2 3 4 5
premium   discount
MDRX 20.12 Peers 34.52   MDRX NM Peers 1.17

Discount. A lower price-to-projected earnings ratio than its peers can signify a less expensive stock or lower future growth expectations.

MDRX is trading at a significant discount to its peers.

 

Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.

MDRX's negative PEG ratio makes this valuation measure meaningless.

 
Price/Book
1 2 3 4 5
premium   discount
  Earnings Growth
1 2 3 4 5
lower   higher
MDRX 1.87 Peers 5.75   MDRX 119.35 Peers 5.78

Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.

MDRX is trading at a significant discount to its peers.

 

Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.

MDRX is expected to have an earnings growth rate that significantly exceeds its peers.

 
Price/Sales
1 2 3 4 5
premium   discount
  Sales Growth
1 2 3 4 5
premium   discount
MDRX 1.84 Peers 5.74   MDRX 1.84 Peers 35.95

Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.

MDRX is trading at a significant discount to its industry on this measurement.

 

Lower. A sales growth rate that trails the industry implies that a company is losing market share.

MDRX significantly trails its peers on the basis of sales growth

 

 

Latest Stock Upgrades/Downgrades